![]() |
|
|
Vol. 296, Issue 1, 84-90, January 2001
Department of Biopharmaceutics, Kyoto Pharmaceutical University,
Kyoto, Japan
The effects of nitric oxide
(NO)
donors NOC5
[3-(2-hydroxy-1-(methylethyl)-2-nitrosohydrazino)-1-propanamine] and
NOC12
[N-ethyl-2-(1-ethyl-hydroxy-2-nitrosohydrazino)-ethanamine] on the permeability of 5(6)-carboxyfluorescein (CF) across the intestinal membrane were examined by an in vitro Ussing chamber method.
The NO donors significantly increased the intestinal permeability of CF
and their absorption-enhancing effects were concentration-dependent over the range of 0.01 to 0.1 mM. Regional differences in the absorption-enhancing effects of the NO donors were observed (colon > jejunum). The absorption-enhancing effect of NOC12 reduced as the
molecular weights of compounds increased. Therefore, the degree of
absorption-enhancing effect of NOC12 was dependent on the molecular weights of compounds. In the pretreatment studies with NOC12 and lactate dehydrogenase release studies, the absorption-enhancing effect
of 0.1 mM NOC12 was reversible and less toxic to the colonic membrane.
On the other hand, the absorption-enhancing effect of NOC12 was
inhibited by the coadministration of 2-(4-carboxyphenyl) 4,4,5,5-tetramethylimidazole-1-oxyl 3-oxide sodium salt, an NO scavenger, suggesting that NO can regulate the permeability of water-soluble drugs in the gut. Furthermore, NOC12 (0.1 and 1 mM)
significantly decreased the transepithelial electrical resistance value
of the colonic membrane, suggesting that the absorption-enhancing mechanism of NOC12 may be partly related to the dilation of the tight
junction in the epithelium via a paracellular route. These findings
suggest that NO donors may be useful to enhance the intestinal absorption of poorly absorbable drugs.
This article has been cited by other articles:
![]() |
N Ara, K Iijima, K Asanuma, J Yoshitake, S Ohara, T Shimosegawa, and T Yoshimura Disruption of gastric barrier function by luminal nitrosative stress: a potential chemical insult to the human gastro-oesophageal junction Gut, March 1, 2008; 57(3): 306 - 313. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kondoh, A. Masuyama, A. Takahashi, N. Asano, H. Mizuguchi, N. Koizumi, M. Fujii, T. Hayakawa, Y. Horiguchi, and Y. Watanbe A Novel Strategy for the Enhancement of Drug Absorption Using a Claudin Modulator Mol. Pharmacol., March 1, 2005; 67(3): 749 - 756. [Abstract] [Full Text] [PDF] |
||||